GlassScriptPhysician profile
Yifei Du
NPI 1073991345
$13,008.33
in general payments reported to CMS, 2019-2025
53 companies · $2,168 in 2025
The $2,168 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,198 · 2020: $1,116 · 2021: $1,727 · 2022: $2,196 · 2023: $2,167 · 2024: $2,436 · 2025: $2,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,691 · Education: $80.28.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,690.73 |
| Education | $80.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,116.84 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $1,672.45 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $1,531.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $1,056.48 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $948.04 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $514.63 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $514.10 | 2022-2025 | Rexulti |
| Indivior INC. | $483.22 | 2019-2025 | Sublocade |
| Almatica Pharma LLC | $332.39 | 2021-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| Allergan, INC. | $308.73 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.60 | 2019-2025 | Xifaxan, Relistor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $292.77 | 2020-2023 | Jardiance |
| Collegium Pharmaceutical, INC. | $279.23 | 2019-2025 | Xtampza, Belbuca |
| Orexo US, INC. | $251.90 | 2019-2025 | Zubsolv |
| Radius Health, INC. | $235.76 | 2024-2025 | Tymlos |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yifei Du listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.